NCT02377856View on ClinicalTrials.gov

Peginterferon Plus Ribavirin Combination Therapy for Hepatitis C Six Months After Onset of Acute Infection

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions

Acute Hepatitis C

Interventions

DRUG

pegylated interferon alpha 2a, ribavirin

pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks

Trial Locations (1)

807

Kaohsiung Medical University Hospital, Kaohsiung, Taiwan., Kaohsiung City

All Listed Sponsors

lead

Kaohsiung Medical University Chung-Ho Memorial Hospital

OTHER

NCT02377856 - Peginterferon Plus Ribavirin Combination Therapy for Hepatitis C Six Months After Onset of Acute Infection | Biotech Hunter | Biotech Hunter